Predictive oncology announces appointment of oncology translational research leader christoph reinhard, ph.d., mba, to its scientific advisory board

Eagan, minn., april 04, 2023 (globe newswire) -- predictive oncology inc. (nasdaq: poai), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, clinical laboratory improvement amendments (clia) laboratory and good manufacturing practices (gmp) facility, to accelerate oncology drug discovery and enable drug development, is pleased to announce the appointment of christoph reinhard, ph.d., mba, to its scientific advisory board. in this role, dr. reinhard will serve alongside other key thought leaders in their respective fields to guide the company's scientific initiatives and growth strategy.
POAI Ratings Summary
POAI Quant Ranking